Induction Chemotherapy for Head and Neck Cancer: Recent Data

被引:42
作者
Vokes, Everett E. [1 ,2 ]
机构
[1] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Med Ctr, Canc Res Ctr, Chicago, IL 60637 USA
关键词
Concurrent chemoradiotherapy; Docetaxel; Induction chemotherapy; Sequential; TPF; LOCALLY ADVANCED HEAD; PHASE-III TRIAL; NEOADJUVANT CHEMOTHERAPY; DOCETAXEL; CISPLATIN; FLUOROURACIL; METAANALYSES;
D O I
10.1634/theoncologist.2010-S3-03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The addition of chemotherapy to radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN) patients improves survival. Meta-analyses of randomized trials have indicated that the benefit of this approach is associated with the timing of chemotherapy administration. It has been demonstrated that the greatest survival benefit over locoregional treatment alone is seen with the concurrent administration of chemotherapy and radiotherapy. However, sequential chemotherapy administration, in the form of induction chemotherapy followed by radiotherapy or concurrent chemoradiotherapy, has been successful as a strategy for organ function preservation in patients with potentially resectable SCCHN. In addition, a meta-analysis of trials using platinum and 5-fluorouracil (PF)-containing induction regimens demonstrated a significant survival benefit for this approach over locoregional treatment alone in locally advanced disease. In recent years, the introduction of the taxanes into induction chemotherapy has provided physicians with more active regimens. The triplet combination induction regimen of docetaxel, cisplatin, and 5-fluorouracil has been shown to be more effective in prolonging survival than the doublet PF. Current trials are testing whether the addition of induction chemotherapy to standard concomitant chemoradiotherapy is superior to concomitant chemoradiotherapy alone. The Oncologist 2010;15(suppl 3):3-7
引用
收藏
页码:3 / 7
页数:5
相关论文
共 13 条
[1]   Individual patients' data meta-analyses in head and neck cancer [J].
Bourhis, Jean ;
Le Maitre, Aurelie ;
Baujat, Bertrand ;
Audry, Helene ;
Pignon, Jean-Pierre .
CURRENT OPINION IN ONCOLOGY, 2007, 19 (03) :188-194
[2]   Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma [J].
Domenge, C ;
Hill, C ;
Lefebvre, JL ;
De Raucourt, D ;
Rhein, B ;
Wibault, P ;
Marandas, P ;
Coche-Dequeant, B ;
Stromboni-Luboinski, M ;
Sancho-Garnier, H ;
Luboinski, B .
BRITISH JOURNAL OF CANCER, 2000, 83 (12) :1594-1598
[3]  
HITT R, 2008, ANN ONCOL, V19
[4]  
HITT R, 2009, J CLIN ONCOL S, V27, pNI181
[5]   End points for new agents in induction chemotherapy for locally advanced head and neck cancers [J].
Monnerat, C ;
Faivre, S ;
Temam, S ;
Bourhis, J ;
Raymond, E .
ANNALS OF ONCOLOGY, 2002, 13 (07) :995-1006
[6]   PHASE-III TRIAL OF INITIAL CHEMOTHERAPY IN STAGE-III OR STAGE-IV HEAD AND NECK CANCERS - A STUDY BY THE GRUPPO-DI-STUDIO-SUI-TUMORI-DELLA-TESTA-E-DEL-COLLO [J].
PACCAGNELLA, A ;
ORLANDO, A ;
MARCHIORI, C ;
ZORAT, PL ;
CAVANIGLIA, G ;
SILENI, VC ;
JIRILLO, A ;
TOMIO, L ;
FILA, G ;
FEDE, A ;
ENDRIZZI, L ;
BARI, M ;
SAMPOGNARO, E ;
BALLI, M ;
GAVA, A ;
PAPPAGALLO, GL ;
FIORENTINO, MV .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (04) :265-272
[7]   Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study [J].
Paccagnella, A. ;
Ghi, M. G. ;
Loreggian, L. ;
Buffoli, A. ;
Koussis, H. ;
Mione, C. A. ;
Bonetti, A. ;
Campostrini, F. ;
Gardani, G. ;
Ardizzoia, A. ;
Dondi, D. ;
Guaraldi, M. ;
Cavallo, R. ;
Tomio, L. ;
Gava, A. .
ANNALS OF ONCOLOGY, 2010, 21 (07) :1515-1522
[8]   Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients [J].
Pignon, Jean-Pierre ;
le Maitre, Aurelie ;
Maillard, Emilie ;
Bourhis, Jean .
RADIOTHERAPY AND ONCOLOGY, 2009, 92 (01) :4-14
[9]   Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:: three meta-analyses of updated individual data [J].
Pignon, JP ;
Bourhis, J ;
Domenge, C ;
Designé, L .
LANCET, 2000, 355 (9208) :949-955
[10]   Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck [J].
Pignon, JP ;
Syz, N ;
Posner, M ;
Olivares, R ;
Le Lann, L ;
Yver, A ;
Dunant, A ;
Lewin, F ;
Dalley, DN ;
Paccagnella, A ;
Taylor, SG ;
Domenge, C ;
Bourhis, J ;
Mazumdar, M .
ANTI-CANCER DRUGS, 2004, 15 (04) :331-340